Ibio Inc Stock News

Shares of iBio Inc. undefined rocketed 64% on heavy volume in premarket trading Friday, as the biotherapeutics and contract manufacturing company is set to...

Shares of iBio Inc. rocketed 64% on heavy volume in premarket trading Friday, as the biotherapeutics and contract manufacturing company is set to be added to the Russell 2000 and Russell 3000 index

NEW YORK, June 26, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics innovator and contract manufacturing organization, today announced that it

NEW YORK, June 24, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announ

IBIO stock has drawn a good deal of interest of late. It's a speculative play with the potential to reward optimistic investors handsomely.

The enthusiasm surrounding iBio stock is warranted since the company is yet to deliver a viable, commercially successful vaccine.

As companies race to develop a Covid-19 vaccine, IBIO stock investors are likely paying too much for a potential manufacturing contract.

Unlike other vaccine stocks, iBio has the tech it needs to scale up manufacturing of its candidate. That makes IBIO stock a buy here.

For investors in search of a novel coronavirus play, IBIO’s puny capitalization and continued one-trick pony press releases are fair warning.

These seven A- and B-rated names are some of the top risky stocks to buy for enterprising investors. Here's what you should know about them.

The novel coronavirus pandemic caught iBio (NYSE:IBIO) stock at a good time.Source: Maksim Shmeljov / Shutterstock.com The company just finished building a 130,000-square-foot facility near Texas A&M;

[Editor's Note: "Sell Moderna (MRNA) Stock as Covid-19 Catalyst Inflates Valuation" was originally published April 2, 2020. It is regularly updated to include the most relevant information.]Source: Sh